Kenneth T. Mills - Jan 2, 2024 Form 4 Insider Report for REGENXBIO Inc. (RGNX)

Role
President and CEO, Director
Signature
/s/ Patrick J. Christmas as attorney-in-fact
Stock symbol
RGNX
Transactions as of
Jan 2, 2024
Transactions value $
-$203,858
Form type
4
Date filed
1/4/2024, 04:07 PM
Previous filing
Dec 21, 2023
Next filing
Jan 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGNX Common Stock Tax liability -$204K -11.4K -3.2% $17.95 344K Jan 2, 2024 Direct F1
transaction RGNX Common Stock Award $0 +64.1K +18.64% $0.00 408K Jan 2, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGNX Stock Options (Right to buy) Award $0 +305K $0.00 305K Jan 2, 2024 Common Stock 305K $18.34 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the issuer's common stock on December 29, 2023.
F2 Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer.
F3 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer.